GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) Chairman Jason Ryan bought 56,742 shares of the company’s stock in a transaction on Thursday, November 16th. The shares were acquired at an average price of $1.27 per share, with a total value of $72,062.34. Following the transaction, the chairman now directly owns 56,742 shares of the company’s stock, valued at $72,062.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Jason Ryan also recently made the following trade(s):
- On Tuesday, October 17th, Jason Ryan sold 42 shares of GeneDx stock. The shares were sold at an average price of $3.19, for a total value of $133.98.
GeneDx Stock Performance
Shares of NASDAQ:WGS opened at $1.39 on Tuesday. GeneDx Holdings Corp. has a 1 year low of $1.16 and a 1 year high of $22.10. The business has a 50 day simple moving average of $2.94 and a two-hundred day simple moving average of $5.18. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.38 and a current ratio of 2.51.
Institutional Trading of GeneDx
Several institutional investors and hedge funds have recently modified their holdings of the stock. Swiss National Bank raised its stake in GeneDx by 7.9% in the first quarter. Swiss National Bank now owns 256,700 shares of the company’s stock worth $788,000 after buying an additional 18,900 shares in the last quarter. Citigroup Inc. raised its stake in GeneDx by 49.2% in the first quarter. Citigroup Inc. now owns 76,541 shares of the company’s stock worth $235,000 after buying an additional 25,236 shares in the last quarter. BlackRock Inc. raised its stake in GeneDx by 5.8% in the first quarter. BlackRock Inc. now owns 2,456,595 shares of the company’s stock worth $7,542,000 after buying an additional 133,789 shares in the last quarter. Vanguard Group Inc. raised its stake in GeneDx by 67.6% in the first quarter. Vanguard Group Inc. now owns 5,518,333 shares of the company’s stock worth $16,941,000 after buying an additional 2,226,502 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in GeneDx by 2.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 626,304 shares of the company’s stock worth $1,923,000 after buying an additional 15,548 shares in the last quarter. Institutional investors own 58.05% of the company’s stock.
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
- Five stocks we like better than GeneDx
- How to Invest in Semiconductors
- The most upgraded stocks in November have two things in common
- What is a SEC Filing?
- Monday.com rocked earnings like it’s the weekend
- Best Aerospace Stocks Investing
- Plan to own one retailer? Make it this one
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.